SCHEMBL25313136

SCHEMBL25313136

FC(F)(F)Oc1cccc(C2(NC[C@H]3CCCN3)CCC2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 4/20 0.41
HDAC6 Q9UBN7 2/20 0.39
HDAC3 O15379 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
SCN9A Q15858 1/20 0.39
KCNN4 O15554 1/20 0.38
CHRNB4 P30926 1/20 0.38
CHRNA3 P32297 1/20 0.38
SLC6A9 P48067 1/20 0.36
CYP2D6 P10635 1/20 0.36
KCNH2 Q12809 1/20 0.36
HTR2C P28335 2/20 0.36
HTR1A P08908 1/20 0.36
HTR2A P28223 1/20 0.36
HRH1 P35367 1/20 0.36
HTR2B P41595 1/20 0.36
SLC6A3 Q01959 1/20 0.36
TMEM97 Q5BJF2 1/20 0.36
SIGMAR1 Q99720 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25314944 1.00 TACR1 (0.41) TACR1HDAC6HDAC3HDAC1HDAC2
SCHEMBL25312630 0.83 SLC6A4 (0.42) SCN9AKCNN4SLC6A3
SCHEMBL25314720 0.83 SLC6A4 (0.42) SCN9AKCNN4SLC6A3
SCHEMBL12480776 0.77 CHRNB4 (0.42) TACR1CHRNB4CHRNA3CYP2D6KCNH2
SCHEMBL12480778 0.77 CHRNB4 (0.42) TACR1CHRNB4CHRNA3CYP2D6KCNH2
SCHEMBL25311806 0.76 KCNN4 (0.50) SCN9AKCNN4CYP2D6KCNH2
SCHEMBL25311480 0.76 KCNN4 (0.50) SCN9AKCNN4CYP2D6KCNH2
SCHEMBL19234331 0.74 CHRNB4 (0.40) TACR1CHRNB4CHRNA3CYP2D6KCNH2
SCHEMBL25313254 0.74 KCNN4 (0.55) KCNN4
SCHEMBL19234330 0.72 HTR6 (0.48) HDAC6HDAC3HDAC1HDAC2SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240034717-A1 NOVEL POTASSIUM CHANNEL INHIBITORS SANIONA A/S (DK) 2024-02-01 US claimed
EP-4217065-A1 NOVEL POTASSIUM CHANNEL INHIBITORS Saniona A/S (DK) 2023-08-02 EP claimed
CN-116368112-A Novel potassium channel inhibitors 萨尼奥纳有限责任公司 2023-06-30 CN claimed
WO-2022063767-A1 NOVEL POTASSIUM CHANNEL INHIBITORS SANIONA A/S (DK) 2022-03-31 WO claimed
US-20240034717-A1 NOVEL POTASSIUM CHANNEL INHIBITORS SANIONA A/S (DK) 2024-02-01 US disclosed
EP-4217065-A1 NOVEL POTASSIUM CHANNEL INHIBITORS Saniona A/S (DK) 2023-08-02 EP disclosed
CN-116368112-A Novel potassium channel inhibitors 萨尼奥纳有限责任公司 2023-06-30 CN disclosed
WO-2022063767-A1 NOVEL POTASSIUM CHANNEL INHIBITORS SANIONA A/S (DK) 2022-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240034717-A1 NOVEL POTASSIUM CHANNEL INHIBITORS KCNN2, KCNJ2, KCNN1 TACR1 1785/4885HDAC6 384/4885HDAC3 280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.